What Is The Current and Historic Market Size Analysis Of The Liraglutide Market?
The liraglutide market has seen considerable growth due to a variety of factors.
• The liraglutide market has experienced strong growth in recent years. It is set to increase from $6.38 billion in 2024 to $6.95 billion in 2025, growing at a CAGR of 9.0%.
The historical growth has been driven by a rising number of type 2 diabetes diagnoses, higher obesity rates, extensive clinical trials, greater awareness of diabetes complications, and innovations in drug delivery systems.
What Are The Predictions for The Liraglutide Market in the Coming Years?
The liraglutide market is expected to maintain its strong growth trajectory in upcoming years.
• The liraglutide market is projected to see strong growth, reaching $9.66 billion by 2029, with a CAGR of 8.6%.
This growth is driven by improved insurance and reimbursement policies, development of healthcare infrastructure, growing awareness and education, an aging population, and the rising prevalence of diabetes. Trends in the forecast period include the use of AI and machine learning, the demand for wearable technology, continuous glucose monitoring, biotechnology advances, and the development of digital health platforms.
Which Drivers Are Accelerating Growth In The Liraglutide Market?
The increasing diabetic population is expected to propel the growth of the liraglutide market. Diabetes, a condition where the body struggles to regulate blood sugar, is becoming more common due to sedentary lifestyles, poor diets, and rising obesity. Liraglutide helps manage diabetes by improving insulin secretion and reducing blood sugar levels. In 2023, 43.8% of people with type 1 diabetes in England received all necessary care processes. As such, the increasing diabetic population is driving the liraglutide market.
What Are The Core Segments Of The Global Liraglutide Market?
The liraglutide market covered in this report is segmented –
1) By Brands: Victoza, Saxenda
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Drug Stores, Online Pharmacies
3) By Type Of Application: Diabetes Treatment, Weight Management
4) By End-Users: Hospitals And Clinics, Homecare Settings
Subsegments:
1) By Victoza: Type 2 Diabetes Treatment Or Weight Management
2) By Saxenda: Weight Loss Treatment Or Obesity Management
Pre-Book The Liraglutide Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Liraglutide Market?
Key players in the liraglutide market are innovating new products, including generic GLP-1, to broaden treatment choices and cater to the market's need for more budget-friendly options. Generic GLP-1 denotes forms of GLP-1 receptor agonists developed post-patent expiry of the original branded medications, which serve as cost-efficient solutions for ailments like type 2 diabetes and obesity. For example, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical enterprise, launched the first generic GLP-1, analogous to Victoza, in the U.S. market in June 2024, fulfilling the growing need for these treatments. Liraglutide injections are recommended for better blood sugar control in adults and children over ten who have type 2 diabetes, and to mitigate the risk of cardiovascular events in adults with type 2 diabetes and pre-existing cardiovascular complications.
Who Are the Key Players In The Liraglutide Market?
Major companies operating in the liraglutide market are:
• Pfizer Inc.
• Roche Holding AG
• Merck & Co. Inc.
• AbbVie Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Novartis International AG
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline Plc
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Biocon Limited
• Hanmi Pharmaceutical Co. Ltd.
• Intarcia Therapeutics Inc.
• Adocia SA
What Are The Regional Insights Into The Liraglutide Market?
North America was the largest region in the liraglutide market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
